Roth Capital Initiates Coverage On Ampio Pharmaceuticals with Buy Rating, Announces $4 Price Target

Roth Capital analyst Jonathan Aschoff initiates coverage on Ampio Pharmaceuticals (AMEX:AMPE) with a Buy rating and a $4 price target.

Benzinga · 12/19/2019 11:38

Roth Capital analyst Jonathan Aschoff initiates coverage on Ampio Pharmaceuticals (AMEX:AMPE) with a Buy rating and a $4 price target.